electroCore Reports Results of Pre-Clinical Trial in a Model of Traumatic Brain Injury
Pre-clinical trial demonstrates the ability of nVNS to decrease the amount of brain injury, decrease anxiety and improve motor function...
Pre-clinical trial demonstrates the ability of nVNS to decrease the amount of brain injury, decrease anxiety and improve motor function...
New research released at ACMG Annual Clinical Genetics Meeting reiterates the superiority of exome sequencing’s role in shortening the diagnostic...
MELBOURNE, Australia and SAN FRANCISCO, March 16, 2023 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”),...
Results from Planned Interim Analysis Expected Fourth Quarter 2023 Approximately 21 Million Adults in U.S. Suffer From a Major Depressive...
NEW YORK, March 03, 2023 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the schedule of data presentations highlighting data...
NEW YORK, Feb. 24, 2023 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced presentations highlighting data from the ULTIMATE I...
Primary Endpoints Demonstrate CTx-1301 Can be Taken With or Without Food CTx-1301 is Designed as a True, Entire Active-Day Treatment...
MARLBOROUGH, Mass. and BERLIN and YOKNEAM ILIT, Israel, Feb. 16, 2023 (GLOBE NEWSWIRE) -- ReWalk Robotics Ltd. (Nasdaq: RWLK) (“ReWalk”...
NEW YORK, Feb. 14, 2023 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the schedule of data presentations highlighting data...
Company to Host Conference Call Today at 1:00pm ET LAVAL, Québec, Feb. 14, 2023 (GLOBE NEWSWIRE) -- Acasti Pharma Inc....
In two of the largest Phase III trials conducted in hidradenitis suppurativa (HS), Cosentyx® (secukinumab) treatment response rates continued to...
IRVINE, Calif., Jan. 31, 2023 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (Nasdaq: RPHM), a clinical-stage pharmaceutical company focused on the...
Study designed to optimize treatment regimen and evaluate efficacy over six-month dosing period Initial results expected in second half of...
Highly experienced and accomplished three-time healthcare CEO with a proven track record of substantial value creation to lead MIMEDX MARIETTA,...
NEW YORK, Jan. 26, 2023 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced the commercial launch of BRIUMVI™...
LAVAL, Québec, Jan. 25, 2023 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti” or the “Company”) (Nasdaq: ACST and TSX-V: ACST),...
Recruitment ongoing in Europe, Asia-Pacific, and the U.S. for study of rapidly progressive Parkinsonian DisorderMELBOURNE, Australia AND SAN FRANCISCO, Jan. 25,...
First placebo-controlled efficacy study completed to date exploring a short-duration psychedelic for depression demonstrates rapid and durable response Primary endpoint...
LAVAL, Québec, Jan. 24, 2023 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti” or the “Company”) (Nasdaq: ACST and TSX-V: ACST),...
FDA sets PDUFA date of May 22, 2023SANTA MONICA, Calif., Jan. 19, 2023 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ:...